Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04WIE
|
|||
| Former ID |
DPR000106
|
|||
| Drug Name |
Sirna-027
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Exudative age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Phase 1/2 | [1] | |
| Neovascular age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Phase 1 | [1] | ||
| Company |
Sirna Therapeutics
|
|||
| SuperDrug ATC ID |
H05AA02
|
|||
| SuperDrug CAS ID |
cas=052232674
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | VEGFR1 messenger RNA (VEGFR1 mRNA) | Target Info | . | [1], [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Transcriptional misregulation in cancer | ||||
| Rheumatoid arthritis | ||||
| Pathway Interaction Database | Glypican 1 network | |||
| HIF-2-alpha transcription factor network | ||||
| S1P3 pathway | ||||
| VEGF and VEGFR signaling network | ||||
| VEGFR1 specific signals | ||||
| Signaling events mediated by VEGFR1 and VEGFR2 | ||||
| Reactome | Neurophilin interactions with VEGF and VEGFR | |||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2011 Pipeline of Sirna Therapeutics. | |||
| REF 2 | Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.